ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Update

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) saw a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 2,400 shares, a drop of 82.9% from the February 28th total of 14,000 shares. Based on an average trading volume of 9,200 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the shares of the company are sold short.

ProShares Ultra Nasdaq Biotechnology Stock Up 0.7 %

Shares of ProShares Ultra Nasdaq Biotechnology stock opened at $50.99 on Friday. The firm has a market cap of $60.17 million, a price-to-earnings ratio of 26.77 and a beta of 1.63. ProShares Ultra Nasdaq Biotechnology has a 52-week low of $47.20 and a 52-week high of $69.56. The company’s 50-day simple moving average is $54.25 and its 200-day simple moving average is $57.46.

ProShares Ultra Nasdaq Biotechnology Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Wednesday, March 26th will be paid a $0.1309 dividend. The ex-dividend date is Wednesday, March 26th. This represents a $0.52 dividend on an annualized basis and a dividend yield of 1.03%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Jane Street Group LLC grew its position in ProShares Ultra Nasdaq Biotechnology by 8.4% during the third quarter. Jane Street Group LLC now owns 4,803 shares of the exchange traded fund’s stock worth $306,000 after buying an additional 374 shares during the period. Crowley Wealth Management Inc. purchased a new position in ProShares Ultra Nasdaq Biotechnology in the 4th quarter valued at approximately $51,000. Finally, Tower Research Capital LLC TRC raised its holdings in ProShares Ultra Nasdaq Biotechnology by 31.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,326 shares of the exchange traded fund’s stock worth $270,000 after purchasing an additional 1,266 shares during the last quarter.

About ProShares Ultra Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.